GRPR and neoplasm: Although studies with GRPR radiopharmaceuticals, including NeoB, have demonstrated high uptake not only in the tumor, but also in the GRPR-expressing pancreas, multiple studies have shown that the pancreas is not expected to be a dose limiting organ for GRPR-mediated treatment (28, 30, 32).